Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23464250 | 0.88 | HDAC2 (0.46) | TSHRALOX15OPRD1OPRK1RORC | |
| SCHEMBL23464262 | 0.86 | OPRD1 (0.44) | TSHRALOX15OPRD1OPRK1GPR119 | |
| SCHEMBL23464183 | 0.85 | GPR119 (0.47) | TSHRALOX15OPRD1OPRK1GPR119 | |
| SCHEMBL23464015 | 0.84 | OPRD1 (0.42) | TSHRALOX15OPRD1OPRK1GPR119 | |
| SCHEMBL23464453 | 0.83 | F13A1 (0.42) | OPRD1OPRK1GPR119STSMEN1 | |
| SCHEMBL23464252 | 0.83 | OPRD1 (0.48) | TSHRALOX15OPRD1OPRK1GPR119 | |
| SCHEMBL23464022 | 0.81 | MEN1 (0.45) | OPRD1OPRK1USP30STSRORC | |
| SCHEMBL20511867 | 0.79 | OPRD1 (0.49) | TSHRALOX15OPRD1OPRK1GPR119 | |
| SCHEMBL29993143 | 0.79 | OPRD1 (0.49) | TSHRALOX15OPRD1OPRK1GPR119 | |
| SCHEMBL23464517 | 0.79 | GPR119 (0.44) | OPRD1OPRK1GPR119USP30ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163420-A1 | Novel Spiro and Cyclic Bis-Benzylidine Proteasome Inhibitor for the Treatment of Cancer, Diabetes and Neurological Disorders | UP THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947199-B2 | Spiro and cyclic bis-benzylidene proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | UP THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2018140907-A1 | NOVEL SPIRO AND CYCLIC BIS-BENZYLIDINE PROTEASOME INHIBITOR FOR THE TREATMENT OF CANCER, DIABETES AND NEUROLOGICAL DISORDERS | UP THERAPEUTICS INC. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947199-B2 | Spiro and cyclic bis-benzylidene proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | ADRM1, PSMC1, PSMB11 | TSHR 1921/4885ALOX15 3897/4885OPRD1 472/4885 |
| US-20210163420-A1 | Novel Spiro and Cyclic Bis-Benzylidine Proteasome Inhibitor for the Treatment of Cancer, Diabetes and Neurological Disorders | ADRM1, PSMC1, PSMB11 | TSHR 2513/4885ALOX15 3647/4885OPRD1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.